Medicine Overview

Indication

Details coming soon

Know Medicine, Follow Guideline

Details coming soon

Adult Dose
Clinical InformationAdministration Information
Indication: Chronic weight management
Age: Adult
Condition: Obesity (initial BMI 30 kg/m2 or greater) or Overweight (initial BMI 27 kg/m2 or greater) with at least one weight-related comorbid condition
Dose: Injection – 0.25 mg
Frequency: once weekly
Duration: 4 weeks
Note: Initiation dose; an adjunct to a reduced calorie diet and increased physical activity; in patients with type 2 diabetes, monitor blood glucose before initiating and during treatment; no dosage adjustment required for hepatic impairment
Indication: Chronic weight management
Age: Adult
Condition: Obesity (initial BMI 30 kg/m2 or greater) or Overweight (initial BMI 27 kg/m2 or greater) with at least one weight-related comorbid condition
Dose: Injection – Dose escalation
Frequency: once weekly
Duration: 4-week intervals
Note: Increase the dose every 4 weeks until a dose of 2.4 mg is reached; if unable to tolerate a dose during escalation, consider delaying dose escalation for 4 weeks

Child Dose
Clinical InformationAdministration Information
Indication: Chronic Weight Management
Age: greater than 12 years
Condition: initial BMI at greater than 95th percentile standardized for age and sex (obesity)
Dose: Subcutaneous Injection – 0.25 mg
Frequency: once weekly
Duration: Weeks 1-4
Note: Indicated as an adjunct to a reduced calorie diet and increased physical activity; refer to prescribing information for BMI cut-offs for obesity by sex and age (CDC Criteria)
Indication: Chronic Weight Management
Age: greater than 12 years
Condition: initial BMI at greater than 95th percentile standardized for age and sex (obesity)
Dose: Subcutaneous Injection – 0.5 mg
Frequency: once weekly
Duration: Weeks 5-8

Renal Dose
Clinical InformationAdministration Information
Condition: Renal impairment
Dose: No dosage adjustment required
Note: Renal impairment No dosage adjustment required
Administration

Administer semaglutide once weekly via subcutaneous injection in the abdomen, thigh, or upper arm at any time of day, with or without meals. Initiate treatment at 0.25 mg weekly for four weeks, followed by a dosage escalation schedule every four weeks until the maintenance dose of 1.7 mg or 2.4 mg is reached. Rotate injection sites weekly and do not mix with insulin if used concomitantly. For missed doses, administer within five days; otherwise, skip the dose and resume the regular schedule. While no dose adjustments are required for elderly patients or those with renal or hepatic impairment, monitor renal function in patients reporting severe adverse gastrointestinal reactions. Usage is contraindicated in patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Discontinue treatment at least two months before a planned pregnancy due to the long washout period.

Side Effect

Drug Interaction

Details coming soon

Disease Interaction

Details coming soon

Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.